Cardiff Oncology to Present at the H.C. Wainwright Global Investment Conference
Cardiff Oncology, Inc. (Nasdaq: CRDF), a biotechnology firm specializing in PLK1 inhibition for cancer therapies, will engage in a fireside chat and one-on-one meetings at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cardiff Oncology, Inc. (Nasdaq: CRDF), a biotechnology firm specializing in PLK1 inhibition for cancer therapies, will engage in a fireside chat and one-on-one meetings at the H.C. Wainwright Global Investment Conference in Miami, Florida, from May 23-26, 2022. The fireside chat is scheduled for May 24, 2022, at 5:00 PM ET. The event is a platform for the company to discuss its innovative therapies, particularly its lead asset, onvansertib, aimed at overcoming treatment resistance in various cancers. A replay will be available on their website following the event.
Details
News Market Reaction – CRDF
The recorded move for CRDF in the trading session of this news was +6.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, May 17, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and one-on-one meetings in-person at the H.C. Wainwright Global Investment Conference, which is taking place in Miami, Florida from May 23 – 26, 2022.
Details on the fireside chat can be found below.
H.C. Wainwright Global Investment Conference | |
Date: | May 24, 2022 |
Time: | 5:00 PM ET |
Webcast Link: | https://journey.ct.events/view/584e1f6d-5db2-432b-888c-7a27b587ea43 |
A replay of the fireside chat will be available by visiting the "Events" section of the Cardiff Oncology website after its conclusion.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
Vicki Kelemen
Chief Operating Officer
858-952-7652
vkelemen@cardiffoncology.com
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-present-at-the-hc-wainwright-global-investment-conference-301548838.html
SOURCE Cardiff Oncology, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.